ImmunoOncology

The company plans to take IGV-001 to the FDA after the mid-stage trial showed a more than six-month improvement in overall survival compared with placebo.

The biotech will present data at the upcoming ASH meeting on three patients who achieved PRs or VGPRs with minimal residual disease negativity and no cases of neurotoxicity.

Sichuan Biokin Pharmaceutical's BMS-partnered bispecific antibody-drug conjugate iza-bren had met both endpoints of PFS and OS in a China-only Phase III trial for the second-line treatment of esophageal squamous cell carcinoma.

The company announced topline results from its Phase III trial in gastroesophageal adenocarcinoma and plans to seek US FDA approval in the first half of 2026.

Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.

The company announced data from patients enrolled after a protocol amendment designed to bring the study in line with non-muscle invasive bladder cancer (NMIBC) standards of care.

Newly revealed data on HLX43’s recommended Phase II/III dose has boosted Henlius’s confidence to launch up to eight Phase III trials of the ADC in lung cancer. Phase III trials of the agent in more cancer types are also on the horizon.

In a China-only Phase III trial, Sichuan Kelun-Biotech’s sac-TMT significantly cut the risk of death by 40% versus chemotherapy in the second-line treatment of non-squamous EGFR-mutated NSCLC. The ADC was administered at a higher dose than in Merck’s multiple Phase III trials of the same agent.

The company presented detailed data at ESMO and said its Phase III trial might have reached statistical significance with a larger sample size.

The company breaks new ground with Keytruda for platinum-resistant ovarian cancer and unveils promising Phase II data on its Daiichi-Sankyo-partnered ADC raludotatug deruxtecan.

Besting BeOne Medicines’ Tevimbra plus chemotherapy, interim results from the head-to-head HARMONi-6 study of Akeso's ivonescimab plus chemotherapy show the combo might have the longest PFS versus its single-target immuno-oncology competitors.

The drugmaker announced positive topline results from the Phase III MajesTEC-3 trial in patients with one to three prior lines of treatment.